The nation of Zimbabwe has turned down a substantial American health deal valued at 367 million US dollars (£272m) spanning five years over Washington's request for confidential data.
This rejection was revealed after a internal memorandum from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government representative has since clarified that the United States was demanding access to biological samples for research and profit while refused to guarantee the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate task of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had furnished over $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged continued negotiations to secure a agreement acceptable to both sides so the nation's vital HIV treatment initiative can proceed.
Broader Background
This rejection comes after a comparable situation in neighbouring Kenya, where a court halted a related deal with the US following legal challenges were filed about the security of Kenyans' medical information.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was pursuing direct bilateral deals to enhance transparency and accountability.
As per reports, 16 African countries have so far agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration would have delivered extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Our nation was requested to share its biological resources and data indefinitely, with no equivalent promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Put simply, our country would provide the basic resources for scientific discovery with no certainty that the end products would be accessible to our citizens if a new disease outbreak arise."
National Interest and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were disrupting frameworks already established through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage potential global health emergencies.
"This framework is designed to guarantee that when a nation contributes its data, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to develop them."
The government's concerns regarding the US deal "are not meant as anti-American sentiment," he added.
"We are open to continued discussions with our US partners on how subsequent collaboration might be structured in a way that honours the independence and interests of each country."
Medical Community Response
A leading public health body said it acknowledged the government's concerns, but recommended that negotiations must proceed considering much of the nation's HIV programmes depended on foreign aid.
"In cases where specific concerns exist, such as those relating to data governance or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," it said.
The situation emphasises the complex debate between accepting crucial international aid and safeguarding national sovereignty in an increasingly data-driven world.